Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.36 |
| ▸ | TACR3 | P29371 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 3/20 | 0.36 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.35 |
| ▸ | GCGR | P47871 | 6/20 | 0.34 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.32 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7066812 | 0.93 | RAD52 (0.39) | TAS1R3TAS1R1TACR3RAD52SMARCA2 | |
| SCHEMBL5886404 | 0.77 | CA12 (0.45) | GCGR | |
| SCHEMBL23583616 | 0.76 | RAD52 (0.48) | TAS1R3TAS1R1TACR3RAD52SMARCA2 | |
| SCHEMBL29406105 | 0.76 | RAD52 (0.48) | TAS1R3TAS1R1TACR3RAD52SMARCA2 | |
| SCHEMBL5886288 | 0.74 | RAD52 (0.47) | TAS1R3TAS1R1TACR3RAD52SMARCA2 | |
| SCHEMBL5886396 | 0.74 | RAD52 (0.47) | TAS1R3TAS1R1TACR3RAD52SMARCA2 | |
| SCHEMBL5886247 | 0.70 | CA12 (0.51) | — | |
| SCHEMBL5886242 | 0.69 | IDO1 (0.40) | ADORA2A | |
| SCHEMBL5886280 | 0.69 | ABL1 (0.39) | ADORA2A | |
| SCHEMBL23583615 | 0.69 | KMT2A (0.35) | RAD52SMARCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030139409-A1 | Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II | XENOVA LIMITED (GB) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139409-A1 | Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II | TOP1, TOP2A, TOP2B | TAS1R3 4053/4885TAS1R1 3054/4885TACR3 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.